Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors.
Pharmacol Rev 2003;55:649–673.
Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine
with concomitant rifampin administration is markedly less than predicted by hepatic
enzyme induction. Clin Pharmacol Ther 1992;52:453–457.
Honkakoski P, Sueyoshi T, Negishi M. Drug-activated nuclear receptors CAR and
PXR. Ann Med 2003;35:172–182.
Houston JB, Galetin A. Modelling atypical CYP3A4 kinetics: principles and
pragmatism. Arch Biochem Biophys 2005;433:351–360.
Houston JB, Kenworthy KE.In vitro–in vivoscaling of CYP kinetic data not consistent with
the classical Michaelis–Menten model.Drug Metab Dispos 2000;28:246– 254.
Ito K, Brown HS, Houston JB. Database analyses for the prediction ofin vivodrug–
drug interactions fromin vitrodata. Br J Clin Pharmacol 2004;57:473–486.
Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T,
Kanamitsu S, Kato M, Kawahara I, Niinuma K, Nishino A, Sato N, Tsukamoto Y,
Ueda K, Itoh T, Sugiyama Y. Which concentration of the inhibitor should be used
to predictin vivodrug interactions fromin vitrodata? AAPS Pharm Sci 2002;4:E25.
Ito K, Hallifax D, Obach RS, Houston JB. Impact of parallel pathways of drug
elimination and multiple cytochrome P450 involvement on drug–drug interactions:
CYP2D6 paradigm. Drug Metab Dispos 2005;33:837–844.
Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. Quantitative prediction of
in vivodrug clearance and drug interactions fromin vitrodata on metabolism, together
with binding and transport. Annu Rev Pharmacol Toxicol 1998a;38:461–499.
Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of
pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction
in the liver. Pharmacol Rev 1998b;50:387–412.
Izzo AA. Drug interactions with St. John’s wort (Hypericum perforatum): a review of the
clinical evidence. Int J Clin Pharmacol Ther 2004;42:139–148.
Kanamitsu S, Ito K, Sugiyama Y. Quantitative prediction of in vivo drug–drug
interactions fromin vitrodata based on physiological pharmacokinetics: use of
maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res
2000;17:336–343.
Kent UM, Juschyshyn MI, Hollenberg PF. Mechanism-based inactivators as probes of
cytochrome P450 structure and function. Curr Drug Metab 2001;2:215–243.
Klaassen CD, Slitt AL. Regulation of hepatic transporters by xenobiotic receptors. Curr
Drug Metab 2005;6:309–328.
Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard
MP, Shou M, Rushmore TH, Trager WF. Electrospray ionization mass spectro-
metric analysis of intact cytochrome P450: identification of tienilic acid adducts to
P450 2C9. Biochemistry 1999;38:2312–2319.
Koenigs LL, Trager WF. Mechanism-based inactivation of cytochrome P450 2B1 by
8-methoxypsoralen and several other furanocoumarins. Biochemistry 1998;37:
13184–13193.
LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK.
Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and
norethindrone. J Clin Pharmacol 1998;38:1042–1050.
132 METABOLISM-MEDIATED DRUG–DRUG INTERACTIONS